A major Alzheimer’s disease medical group is recommending that specialists may use certain blood tests to help diagnose ...

ALZpath’s pTau217 antibody is drawing significant attention at this year’s Alzheimer's Association International Conference (AAIC), taking place in Toronto, Canada, from 27-31 July. The biomarker ...

A new blood test is being called a game changer for helping diagnose Alzheimer’s, and UNLV helped contribute research to it.

Know how a groundbreaking brain scan could revolutionise Alzheimer's detection. Understand from an expert how this innovative technology may identify the disease years before symptoms appear.

The combination of a recently approved blood test for detection of Alzheimer's disease combined with two medications that slow progression of the disease is drastically improving outcomes for patients ...

In a Phase Ib/IIa trial, 91% of patients receiving the highest dose of trontinemab were amyloid negative after seven months of treatment, representing what B. Riley Securities called a “paradigm shift ...

Roche has added another phase 3 trial in its programme for Alzheimer's disease candidate trontinemab and will now test the ...

Trontinemab's Phase Ib/IIa Brainshuttle AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative and ARIA-E remaining Design of the Phase III TR ...

Trontinemab’s Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust clearance of amyloid plaques, with 91% ...

Mayo Clinic researchers have developed a new artificial intelligence (AI) tool that helps clinicians identify brain activity ...